FOSAPREPITANT Drug Patent Profile
✉ Email this page to a colleague
When do Fosaprepitant patents expire, and what generic alternatives are available?
Fosaprepitant is a drug marketed by Accord Hlthcare, Apotex, Aspiro, Baxter Hlthcare Corp, Be Pharms, Caplin, Chia Tai Tianqing, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Geneyork Pharms, Lupin, MSN, Mylan Labs Ltd, Navinta Llc, Piramal Critical, Praxgen, Qilu Pharm Hainan, and Teva Pharms Usa. and is included in nineteen NDAs.
The generic ingredient in FOSAPREPITANT is fosaprepitant dimeglumine. There are eleven drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fosaprepitant
A generic version of FOSAPREPITANT was approved as fosaprepitant dimeglumine by FRESENIUS KABI USA on June 9th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FOSAPREPITANT?
- What are the global sales for FOSAPREPITANT?
- What is Average Wholesale Price for FOSAPREPITANT?
Summary for FOSAPREPITANT
| US Patents: | 0 |
| Applicants: | 19 |
| NDAs: | 19 |
| Drug Prices: | Drug price information for FOSAPREPITANT |
| What excipients (inactive ingredients) are in FOSAPREPITANT? | FOSAPREPITANT excipients list |
| DailyMed Link: | FOSAPREPITANT at DailyMed |
Recent Clinical Trials for FOSAPREPITANT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Montefiore Medical Center | PHASE4 |
| Helsinn Healthcare SA | PHASE2 |
| Qilu Pharmaceutical Co., Ltd. | PHASE3 |
US Patents and Regulatory Information for FOSAPREPITANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | FOSAPREPITANT DIMEGLUMINE | fosaprepitant dimeglumine | POWDER;INTRAVENOUS | 204025-001 | Aug 26, 2020 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Praxgen | FOSAPREPITANT DIMEGLUMINE | fosaprepitant dimeglumine | POWDER;INTRAVENOUS | 213199-001 | Oct 4, 2021 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Chia Tai Tianqing | FOSAPREPITANT DIMEGLUMINE | fosaprepitant dimeglumine | POWDER;INTRAVENOUS | 212143-001 | Mar 3, 2021 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Baxter Hlthcare Corp | FOSAPREPITANT DIMEGLUMINE | fosaprepitant dimeglumine | POWDER;INTRAVENOUS | 211860-001 | Sep 5, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
